<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">NM</journal-id><journal-title-group><journal-title>Neuroscience and Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-2912</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/nm.2019.101002</article-id><article-id pub-id-type="publisher-id">NM-91188</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Amylotrophic Lateral Sclerosis-Like Motor Impairment in Prion Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eden</surname><given-names>Yitna Teferedegn</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dawit</surname><given-names>Tesfaye</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eyualem</surname><given-names>Abebe</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Cemal</surname><given-names>Un</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Department of Natural Sciences, Elizabeth City State University, Elizabet City, NC, USA</addr-line></aff><aff id="aff2"><addr-line>Institute for Animal Science, University of Bonn, Bonn, Germany</addr-line></aff><aff id="aff1"><addr-line>Department of Biology, Molecular Biology Division, Ege University, Izmir, Turkey</addr-line></aff><pub-date pub-type="epub"><day>14</day><month>01</month><year>2019</year></pub-date><volume>10</volume><issue>01</issue><fpage>15</fpage><lpage>29</lpage><history><date date-type="received"><day>2,</day>	<month>January</month>	<year>2019</year></date><date date-type="rev-recd"><day>15,</day>	<month>March</month>	<year>2019</year>	</date><date date-type="accepted"><day>18,</day>	<month>March</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Neurodegenerative diseases are collective diseases that affect different parts of the brain with common or distinct disease phenotype. In almost all of the Prion diseases, motor impairments that are characterized by motor derangement, apathy, ataxia, and myoclonus are documented and again are shared by motor neuron diseases (MND). Proteins such as; B-Cell lymphoma 2 (BCL2), Copper chaperone for superoxide dismutase (CCS), Amyloid beta precursor protein (APP), Amyloid Precursor-Like Protein1/2 (APLP1/2), Catalase (CAT), and Stress induced phosphoprotein 1 (STIP1), are common interactomes of Prion and superoxide dismutase 1 (SOD1). Although there is no strong evidence to show the interaction of SOD1 and Prion, the implicated common interacting proteins indicate the potential bilateral interaction of those proteins in health and disease. For example, down-regulation of Heat shock protein A (HSPA5), a Prion interactome, increases accumulation of misfolded SOD1 leading to MND. Loss of Cu uptake function disturbs normal function of CCS. Over-expressed proteasome subunit alpha 3 (PSMA3) could fatigue its normal function of removing misfolded proteins. Studies showed the increase in CAT and lipid oxidation both in Prion-knocked out animal and in catalase deficiency cases. Up regulation, down regulation or direct interaction with their interactomes are predicted molecular mechanisms by which Prion and SOD exert their effect. The loss of protective function or the gain of a novel toxic property by the principal proteins is shared in Prion and MND. Thus, it might be possible to conclude that the interplay of proteins displayed in both diseases could be a key phenomenon in motor dysfunction development.
 
</p></abstract><kwd-group><kwd>Prion</kwd><kwd> Super Oxide Dismutase-1</kwd><kwd> Amyotrophic Lateral Sclerosis</kwd><kwd> Motor Neuron Diseases</kwd><kwd> Interactomes</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Neurodegenerative disease is a global concern and poses serious social and individual challenges. Seen in light of financial limitations and resource allocation, developing countries are specifically currently challenged by a wide variety of neurodegenerative diseases [<xref ref-type="bibr" rid="scirp.91188-ref1">1</xref>] . Alzheimer, Parkinson, Huntington, and dementia are the most common diseases that degenerate neurons. Apart from those, Prion diseases are characterized as the lethal form of neurodegenerative diseases with no clearly defined molecular mechanism and cure. Among the different types of Prion diseases, Kuru is one of the oldest that was discovered in New Guinea [<xref ref-type="bibr" rid="scirp.91188-ref2">2</xref>] . Later, Creudzfelt-Jacob Disease (CJD) was identified for the first time in the UK in late 1990s [<xref ref-type="bibr" rid="scirp.91188-ref3">3</xref>] .</p><p>Here we attempt to focus on the predictable molecular mechanism of motor impairment which is manifested in patients of Prion diseases. The basis for the predicative pathomechanism is the absence of evidence of definite physiologic function of cellular Prion [<xref ref-type="bibr" rid="scirp.91188-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref7">7</xref>] . There are knock-out and knock-down studies which show the gain and/or loss of Prion functions and its effect on the expression level of other proteins [<xref ref-type="bibr" rid="scirp.91188-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref11">11</xref>] . Moreover, there is presumption that the normal physiologic function of cellular Prion depends on other proteins that interact with it [<xref ref-type="bibr" rid="scirp.91188-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref12">12</xref>] . For example, up-regulation of superoxide dismutase (SOD) by cellular Prion is one of the many pieces of evidence to illustrate the physiologic function of Prion [<xref ref-type="bibr" rid="scirp.91188-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref14">14</xref>] . Some of the clinical features that are implicated in Prion diseases might be because of the same molecular phenomena of other diseases which are explained by up-regulation, down-regulation or abnormal interaction with the specific protein.</p></sec><sec id="s2"><title>2. Prion and Prion Diseases Pathogenesis</title><p>Prion protein is highly expressed in brain cells [<xref ref-type="bibr" rid="scirp.91188-ref15">15</xref>] by a single copy PRNP gene [<xref ref-type="bibr" rid="scirp.91188-ref16">16</xref>] and it is a transmembrane protein which undergoes multiple post-translational modifications [<xref ref-type="bibr" rid="scirp.91188-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref18">18</xref>] . Cleavage of 22 aa from N terminal signal peptide, cleavage of 23 aa from C terminal and addition of GPI anchor, disulfide bond, and glycosylation are the well-documented post-translational modification which might affect its higher order structure and its interaction with its interactomes [<xref ref-type="bibr" rid="scirp.91188-ref19">19</xref>] . The sum total effect may contribute to species and strain specific barrier phenomenon [<xref ref-type="bibr" rid="scirp.91188-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref22">22</xref>] .</p><p>Prion diseases are among the very rear lethal disease of both humans and animals [<xref ref-type="bibr" rid="scirp.91188-ref23">23</xref>] . Though there are a number of studies, there are still unconfirmed issues about biological structure, defined molecular pathophysiology and the mechanism how selective cross-species infections take place [<xref ref-type="bibr" rid="scirp.91188-ref24">24</xref>] . Despite the low rate of prevalence, its non-curability, within and cross-species transmissibility and lethality make Prion diseases one of the most debilitating diseases of our time.</p><p>Prion diseases are principally caused by abnormally misfolded Prion proteins which are capable of replicating themselves by recruiting normal cellular Prion and later amyloidosis [<xref ref-type="bibr" rid="scirp.91188-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref26">26</xref>] . vCJD, CJD, GSS, FFI are among the most characterized human Prion diseases classified based on whether they are sporadic, acquired or inherited [<xref ref-type="bibr" rid="scirp.91188-ref27">27</xref>] . In most instances, the duration of incubation varies for different variants of Prion [<xref ref-type="bibr" rid="scirp.91188-ref28">28</xref>] . Apart from that, the onset of the disease is the basis for classification of Prion diseases [<xref ref-type="bibr" rid="scirp.91188-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref30">30</xref>] . Histological studies revealed that thalamus, brain stem, and cerebellum are the most affected brain parts by the majority of Prion strain [<xref ref-type="bibr" rid="scirp.91188-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref31">31</xref>] . Almost all of the human Prion diseases share common clinical features: anxiety, depression, hyperactivity are the commonest psychiatric clinical features while dementia [<xref ref-type="bibr" rid="scirp.91188-ref32">32</xref>] , motor derangement, apathy, ataxia, myoclonus tremor and at later stage mutism, Pyramidal, and extrapyramidal dysfunctions are the pronounced neurological disorders [<xref ref-type="bibr" rid="scirp.91188-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref34">34</xref>] .</p></sec><sec id="s3"><title>3. Development of Motor Neuron Impairment</title><sec id="s3_1"><title>3.1. Types and Etiology of Motor Neuron Diseases</title><p>Among the most distinct clinical symptoms of Prion diseases, motor impairment is the commonest at the different stages of disease development. The symptom resembles clinical features of motor neuron diseases where both or either of Upper motor neuron (UMN) or lower motor neuron (LMN) that arise from spine and brain innervating muscles are degenerated [<xref ref-type="bibr" rid="scirp.91188-ref35">35</xref>] . Based on the cause, severity, clinical presentation and onset of the disease, motor neuron disease (MND) are classified as amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), hereditary spastic paraplegias (HSP), and progressive bulbar palsy (PBP) [<xref ref-type="bibr" rid="scirp.91188-ref36">36</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref37">37</xref>] . ALS is the most common that affect both UMN and LMN neurons. Majority of ALS cases are sporadic though it can also be familial [<xref ref-type="bibr" rid="scirp.91188-ref35">35</xref>] . ALS is caused by a number of mutations in Cu/Zn superoxide dismutase-1 gene, ALS, cytoplasmic dynein and dynactin, D-amino acid oxidase DAO and Optineurin OPTN, Chromosome 9 open reading frame 72C9ORF72 and others [<xref ref-type="bibr" rid="scirp.91188-ref38">38</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref39">39</xref>] . Mutation to superoxide dismutase1 (SOD) is the main cause of ALS next to mutation to C9ORF72 hexanucleotide repeat in the promoter region [<xref ref-type="bibr" rid="scirp.91188-ref38">38</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref40">40</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref41">41</xref>] . One of the most notable pathogenesis of this disease is glutamate-induced excitotoxicity that disrupts Ca<sup>2+</sup> homeostasis to cause motor neuron death [<xref ref-type="bibr" rid="scirp.91188-ref42">42</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref43">43</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref44">44</xref>] . Apart from that, oxidative distress and axonal transport dysfunction cause neural injury through metal (Cu, iron, Zn) homeostatic disturbance [<xref ref-type="bibr" rid="scirp.91188-ref33">33</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref46">46</xref>] . BCL2-mediated Apoptosis, protein aggregation and autophagy are also part of pathomechanisms of ALS disease development [<xref ref-type="bibr" rid="scirp.91188-ref47">47</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref48">48</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref49">49</xref>] . As in familial Prion diseases, ALS is autosomal dominant [<xref ref-type="bibr" rid="scirp.91188-ref50">50</xref>] . The other type of MDN which mostly arises in the medulla is progressive bulbar palsy. Among inheritable MDN disease, spinal muscular atrophy (SMA) is autosomal recessive that affects LMN [<xref ref-type="bibr" rid="scirp.91188-ref51">51</xref>] where its molecular basis is an alteration in the survival motor neuron gene [<xref ref-type="bibr" rid="scirp.91188-ref52">52</xref>] .</p></sec><sec id="s3_2"><title>3.2. Pathogenesis and Clinical Presentation of MND</title><p>Neurons of the spinal cord, brain stem, cerebellum, cerebral cortex, and basal ganglia are most affected by MND [<xref ref-type="bibr" rid="scirp.91188-ref53">53</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref54">54</xref>] . Like in Prion diseases, histological studies revealed that there is also vastrogliosis [<xref ref-type="bibr" rid="scirp.91188-ref55">55</xref>] and microglial activation in MND [<xref ref-type="bibr" rid="scirp.91188-ref56">56</xref>] . Moreover, spongiosis-microvaculation is frequently documented in frontal and temporal cortices particularly in FTLD [<xref ref-type="bibr" rid="scirp.91188-ref57">57</xref>] . Progressive skeletal muscle weakness, wasting, fatigability, the difficulty of movement and gait disturbance, extrapyramidal diseases, tremor, atrophy, the difficulty of swallowing and other emotional disorders like anxiety, depression, excitability, dementia, and insomnia are all implicated in the majority of MND [<xref ref-type="bibr" rid="scirp.91188-ref58">58</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref59">59</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref60">60</xref>] .</p></sec></sec><sec id="s4"><title>4. Motor Impairment in Prion Diseases that Resembles ALS</title><sec id="s4_1"><title>4.1. Prion and SOD1 Interactomes in Health and Disease</title><p>As indicated above, the function of Prion is studied in relation to loss or gain of functions. In some, in in-vivo studies the knocking out/knocking down of genes or challenging Prion expression had little to no effect on the normal cellular function and/or brings no known disease phenotype [<xref ref-type="bibr" rid="scirp.91188-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref61">61</xref>] . As a result, its biological function may be through proteins that it interacts with under the normal physiologic conditions.</p><p>Prion protein is implicated in several signaling pathways having a wide range of functions from cell differentiation [<xref ref-type="bibr" rid="scirp.91188-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref62">62</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref63">63</xref>] to apoptosis [<xref ref-type="bibr" rid="scirp.91188-ref64">64</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref65">65</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref66">66</xref>] . Prion protein forms interaction network with a wide variety of proteins intracellularly (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>). Findings showed that proteins such as Stress induced phosphoprotein 1 (STIP1) [<xref ref-type="bibr" rid="scirp.91188-ref67">67</xref>] , Heat Shock Protein A4 (HSPA4) Clustrin (CLU) [<xref ref-type="bibr" rid="scirp.91188-ref68">68</xref>] , Heat shock protein family A (HSPA5) [<xref ref-type="bibr" rid="scirp.91188-ref69">69</xref>] , Argonaute-1 (AGO1) [<xref ref-type="bibr" rid="scirp.91188-ref70">70</xref>] , BCL2 Associated Athanogene 6 BAG6 [<xref ref-type="bibr" rid="scirp.91188-ref71">71</xref>] , and N-myc and STAT interactor (NML) are the most characterized interactomes of Prion [<xref ref-type="bibr" rid="scirp.91188-ref72">72</xref>] - [<xref ref-type="bibr" rid="scirp.91188-ref79">79</xref>] . B-Cell lymphoma 2 (BCL2) [<xref ref-type="bibr" rid="scirp.91188-ref80">80</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref81">81</xref>] , Smith-Magenis syndrome chromosome region, candidate 8 (SMCR8), Proteasome subunit alpha 3 (PSMA3), Copper chaperone for superoxide dismutase (CCS) [<xref ref-type="bibr" rid="scirp.91188-ref82">82</xref>] , Amyloid beta precursor protein (APP) [<xref ref-type="bibr" rid="scirp.91188-ref83">83</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref84">84</xref>] , Amyloid Precursor-Like Protein (1APLP1/2) [<xref ref-type="bibr" rid="scirp.91188-ref85">85</xref>] , WD repeat domain (5WDR5), Homeobox (A1HOXA1) [<xref ref-type="bibr" rid="scirp.91188-ref86">86</xref>] , and Catalase (CAT) [<xref ref-type="bibr" rid="scirp.91188-ref87">87</xref>] are identified to interact with Prion with a variety of cellular function. CCS and CAT are especially involved in oxidative stress [<xref ref-type="bibr" rid="scirp.91188-ref88">88</xref>] . BAG6, PSMA3, and SMCR8 are involved in proteolytic degradation of misfolded protein and autophagy. Heat shock protein family A44 and HSPA5 are chaperones that are involved in the folding and refolding of misfolded proteins in response to cellular stress [<xref ref-type="bibr" rid="scirp.91188-ref89">89</xref>] . BCL2, NML, and CLU, are mostly known for their role in either pro or anti-apoptosis activities [<xref ref-type="bibr" rid="scirp.91188-ref90">90</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref91">91</xref>] . Copper chaperone for superoxide dismutase, CAT, HSPA4, SMCR8, Cone-rod homeobox (CRX), N-myc and STAT interactor (NMI), and</p><p>Ubiquitin C (UBC) [<xref ref-type="bibr" rid="scirp.91188-ref79">79</xref>] are common proteins that interact with Prion, SOD1, and C9ORF72. Similarly, Adenylate kinase 2 AK2, HSPA5, HSPA2 [<xref ref-type="bibr" rid="scirp.91188-ref78">78</xref>] , HSPH1, SOD2 [<xref ref-type="bibr" rid="scirp.91188-ref73">73</xref>] are especially known to interact with SOD1.</p></sec><sec id="s4_2"><title>4.2. The Interplay of Interactomes in Motor Neuron Impairment (MNI)</title><p>Considering the presumable and potential interaction between Prion and SOD in disease pathogenesis, it is worth to take into account the interplay between Prion and SOD1 through their interacting proteins which are common for both. The expression of SOD is somehow influenced by the level of PrP<sup>c</sup> [<xref ref-type="bibr" rid="scirp.91188-ref92">92</xref>] . In another way, the loss of SOD1 up-regulating property of Prion would rather exacerbate oxidative stress which results in cell death. However, there are reports that show PrP<sup>c</sup> having no SOD activity whatsoever [<xref ref-type="bibr" rid="scirp.91188-ref93">93</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref94">94</xref>] . If the loss of SOD1 upregulating function of the Prion is indeed the cause for SOD1 dysfunction, then abrupt mitochondria-based oxidative stress and cell death would be expected.</p><p>Both Prion and SOD1 have a role in metal regulation and homeostasis [<xref ref-type="bibr" rid="scirp.91188-ref94">94</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref95">95</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref96">96</xref>] . Conversions of cellular Prion to scrapie form cause derangement of Ca<sup>2+</sup> homeostasis [<xref ref-type="bibr" rid="scirp.91188-ref97">97</xref>] . Further Ca<sup>2+</sup> homeostatic imbalance continues to occur when the L-type voltage-sensitive Ca<sup>2+</sup> channel is affected by oxidative stress. As part of the signaling process that Prion plays, infective form of Prion is assumed to disrupt Ca-activated K current [<xref ref-type="bibr" rid="scirp.91188-ref98">98</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref99">99</xref>] . The sum total effects of electron imbalance could be the cause of impaired neural excitability which leads to motor impairment.</p><p>In some studies, Prion peptides are documented to cause down-regulation of HSPA5 expression. The same phenomenon can be extrapolated for misfolded protein to downregulate known chaperons [<xref ref-type="bibr" rid="scirp.91188-ref100">100</xref>] . Likewise, impaired chaperons could also lose their protective effect of firing signal under stressful condition [<xref ref-type="bibr" rid="scirp.91188-ref101">101</xref>] . That often could accompany with endoplasmic reticulum stress-associated cell death [<xref ref-type="bibr" rid="scirp.91188-ref102">102</xref>] . By the same mechanism, down-regulation of HSPA5 may increase accumulation of misfolded SOD1 leading to MND. Thus, it might be possible to conclude HSPA5 regulation in both diseases is a key phenomenon in motor dysfunction development [<xref ref-type="bibr" rid="scirp.91188-ref103">103</xref>] .</p><p>Experimental evidence confirms CCS maintains SOD [<xref ref-type="bibr" rid="scirp.91188-ref104">104</xref>] . The Cu served to SOD is taken up by the Prion. Loss of Cu uptake function disturbs normal function of CCS [<xref ref-type="bibr" rid="scirp.91188-ref30">30</xref>] . As a result, SOD is unable to perform its normal cellular functions. Accumulation of Cu in cytosol causes up-regulation of cellular Prion under physiologic conditions [<xref ref-type="bibr" rid="scirp.91188-ref96">96</xref>] . Misfolded Prion seed, according to Refolding Hypothesis, recruits cellular Prions as their own substrate [<xref ref-type="bibr" rid="scirp.91188-ref105">105</xref>] . It is possible to predict that upon up-regulation of Prion by Cu might further potentiate misfolded aggregate to form amyloid. In addition to this effect, either physical axonal transport blockage and/or an increase in oxidative stress kills neurons. Studies showed extracellular Cu also control expression and turnover of PrP<sup>c</sup> in neurons. The transport of Prion from neuron to astrocyte is somehow mediated by extracellular Cu [<xref ref-type="bibr" rid="scirp.91188-ref96">96</xref>] . In turn, PrP<sup>c</sup> participates in Cu transport from neuron to astrocyte. This complementary function protects the cell from Cu toxicity [<xref ref-type="bibr" rid="scirp.91188-ref106">106</xref>] . When PrP<sup>c</sup> loses this protective function, the concentration of Cu might increase both in extracellular space, astrocytes and other neurons. An invitro study also showed Cu to enhance renaturation and stabilization of PrPSc, and again further boost its resistance and infectivity [<xref ref-type="bibr" rid="scirp.91188-ref107">107</xref>] .</p><p>PrPSc cause downregulation of PSMA3. In this case, there might be the bulk removal of cells [<xref ref-type="bibr" rid="scirp.91188-ref108">108</xref>] . Overexpressed PSMA3 could fatigue its own normal function of removing misfolded proteins [<xref ref-type="bibr" rid="scirp.91188-ref109">109</xref>] . Such condition brings in a toxic gain function of Prion and loss of protective function of SOD causing motor neuron death [<xref ref-type="bibr" rid="scirp.91188-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref110">110</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref111">111</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref112">112</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref113">113</xref>] . CAT is another very important protein in processing reactive oxygen species together with SOD [<xref ref-type="bibr" rid="scirp.91188-ref114">114</xref>] . Protein and lipid oxidation increase in Prion knocked out and catalase deficient model animals [<xref ref-type="bibr" rid="scirp.91188-ref111">111</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref115">115</xref>] . The synergetic effect of a decrease in catalytic activity and increased oxidation could result in neural death.</p><p>Under the physiologic condition, Clusterin is a ligand for PrP<sup>c</sup> [<xref ref-type="bibr" rid="scirp.91188-ref68">68</xref>] . In Prion diseased sample, Clusterin is believed to form an aggregate with misfolded Prion [<xref ref-type="bibr" rid="scirp.91188-ref116">116</xref>] . That might suggest a structural change which challenges the interaction of Clusterin and Prion. As a result, removal of aggregates might be boldly jeopardized. Aggregates and precipitations are the prominent cause of cell death. Proteins in UPS and autophagy are the other molecular phenomenon that is frequently mentioned in trafficking and maintaining the normal cellular function of Prion [<xref ref-type="bibr" rid="scirp.91188-ref101">101</xref>] . These systems are important machineries playing the role of removing misfolded proteins. Dysfunctional proteins, misfolded proteins, are believed to possess structures that potentially challenge interactions with chaperones for degradation. Ub and NMI are among the many proteins that are displayed in UPS and autophagy of neurodegenerative disease [<xref ref-type="bibr" rid="scirp.91188-ref101">101</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref116">116</xref>] . Those proteins are documented to interact with Prion and SOD. AGO is an interesting protein with a critical function in the regulation of miRNA. Ago regulate protein translation through its catalytic action by forming a complex called RISC with miRNA [<xref ref-type="bibr" rid="scirp.91188-ref117">117</xref>] [<xref ref-type="bibr" rid="scirp.91188-ref118">118</xref>] . It is also an interactome to Prion [<xref ref-type="bibr" rid="scirp.91188-ref119">119</xref>] and potentially to SOD. Any abnormal interaction with dysfunctional proteins can potentially subvert normal function of AGO and threaten cell survival. And again, the loss of interaction with those key proteins might be the reason for the development of the disease (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec></sec><sec id="s5"><title>5. Conclusion</title><p>The molecular basis described in the review of cell death through a different mechanism in relation to either the loss of protective function or the gain of a novel toxic properties is shared by both Prion diseases and MND especially ALS. In conclusion, here we tried to show the similarity between the molecular basis of motor impairment in ALS and Prion diseases. Despite they are distinct from each other, the interplay of proteins displayed in both cases can tell a lot about pathomechanism of motor impairment in Prion diseases. Thus, with further experimental studies it is worth to confirm the molecular mechanism of motor</p><p>impairments of Prion diseases in order to identify potential therapeutic approaches.</p></sec><sec id="s6"><title>Funding</title><p>No funding was received for this work.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Teferedegn, E.Y., Tesfaye, D., Abebe, E. and Un, C. (2019) Amylotrophic Lateral Sclerosis-Like Motor Impairment in Prion Diseases. Neuroscience &amp; Medicine, 10, 15-29. https://doi.org/10.4236/nm.2019.101002</p></sec></body><back><ref-list><title>References</title><ref id="scirp.91188-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sosso, F.A.E. and Kabore, P. (2016) The African Burden of Mental Health. Journal of Mental Disorders and Treatment, 2, 1222.  
https://doi.org/10.4172/2471-271X.1000122</mixed-citation></ref><ref id="scirp.91188-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Liberski, P.P. (2013) Kuru: A Papua New Guinea to the Neanderthals’ Extinction. Pathogens, 2, 472-505. https://doi.org/10.3390/pathogens2030472</mixed-citation></ref><ref id="scirp.91188-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">NPR.org. (2017) When People Ate People, a Strange Disease Emerged.  
https://www.npr.org/sections/thesalt/2016/09/06/482952588/when-people-ate-people-a-strange-disease-emerged</mixed-citation></ref><ref id="scirp.91188-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Almond, J.W. (1998) Bovine Spongiform Encephalopathy and New Variant Creutzfeldt-Jakob Disease. British Medical Bulletin, 54, 749-759.  
https://doi.org/10.1093/oxfordjournals.bmb.a011724</mixed-citation></ref><ref id="scirp.91188-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Collinge, J., et al. (1994) Prion Protein Is Necessary for Normal Synaptic Function. Nature, 370, 295-297. https://doi.org/10.1038/370295a0</mixed-citation></ref><ref id="scirp.91188-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dormont, D. (2002) Prion Diseases: Pathogenesis and Public Health Concerns. FEBS Letters, 529, 17-21. https://doi.org/10.1016/S0014-5793(02)03268-4</mixed-citation></ref><ref id="scirp.91188-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Choi, D.K., Kim, I.S. and Do, J.H. (2014) Signaling Pathway Analysis of MPP&lt;sup&gt;+&lt;/sup&gt;-Treated Human Neuroblastoma SH-SY5Y Cells. Biotechnology and Bioprocess Engineering, 19, 332-340. https://doi.org/10.1007/s12257-013-0754-x</mixed-citation></ref><ref id="scirp.91188-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">La Mendola, D., et al. (2008) Prion Proteins Leading to Neurodegeneration. Current Alzheimer Research, 5, 579-590. https://doi.org/10.2174/156720508786898415</mixed-citation></ref><ref id="scirp.91188-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Martins, V.R., et al. (2001) Insights into the Physiological Function of Cellular Prion Protein. Brazilian Journal of Medical and Biological Research, 34, 585-595.  
https://doi.org/10.1590/S0100-879X2001000500005</mixed-citation></ref><ref id="scirp.91188-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lee, K.J., et al. (2007) Cellular Prion Protein (PrPC) Protects Neuronal Cells from the Effect of Huntingtin Aggregation. Journal of Cell Science, 120, 2663-2671.  
https://doi.org/10.1242/jcs.004598</mixed-citation></ref><ref id="scirp.91188-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Westergard, L., Christensen, H.M. and Harris, D.A. (2007) The Cellular Prion Protein (PrPC): Its Physiological Function and Role in Disease. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1772, 629-644.  
https://doi.org/10.1016/j.bbadis.2007.02.011</mixed-citation></ref><ref id="scirp.91188-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Solomon, I.H., Schepker, J.A. and Harris, D.A. (2010) Prion Neurotoxicity: Insights from Prion Protein Mutants. Current Issues in Molecular Biology, 12, 51-61.</mixed-citation></ref><ref id="scirp.91188-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Castle, A.R. and Gill, A.C. (2017) Physiological Functions of the Cellular Prion Protein. Frontiers in Molecular Biosciences, 4, 19.  
https://doi.org/10.3389/fmolb.2017.00019</mixed-citation></ref><ref id="scirp.91188-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kozlowski, H., et al. (2009) Copper, Iron, and Zinc Ions Homeostasis and Their Role in Neurodegenerative Disorders (Metal Uptake, Transport, Distribution and Regulation). Coordination Chemistry Reviews, 253, 2665-2685.  
https://doi.org/10.1016/j.ccr.2009.05.011</mixed-citation></ref><ref id="scirp.91188-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Onodera, T. (2017) Dual Role of Cellular Prion Protein in Normal Host and Alzheimer’s Disease. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences, 93, 155-173. https://doi.org/10.2183/pjab.93.010</mixed-citation></ref><ref id="scirp.91188-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">McKinley, M.P., et al. (1987) Developmental Expression of Prion Protein Gene in Brain. Developmental Biology, 121, 105-110.  
https://doi.org/10.1016/0012-1606(87)90143-6</mixed-citation></ref><ref id="scirp.91188-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Ciric, D. and Rezaei, H. (2015) Biochemical Insight into the Prion Protein Family. Frontiers in Cell and Developmental Biology, 3, 5.  
https://doi.org/10.3389/fcell.2015.00005</mixed-citation></ref><ref id="scirp.91188-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Harris, D.A. (1999) Cellular Biology of Prion Diseases. Clinical Microbiology Reviews, 12, 429-444. https://doi.org/10.1128/CMR.12.3.429</mixed-citation></ref><ref id="scirp.91188-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Otvos, L. and Cudic, M. (2002) Post-Translational Modifications in Prion Proteins. Current Protein &amp; Peptide Science, 3, 643-652.  
https://doi.org/10.2174/1389203023380440</mixed-citation></ref><ref id="scirp.91188-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Duan, G. and Walther, D. (2015) The Roles of Post-Translational Modifications in the Context of Protein Interaction Networks. PLoS Computational Biology, 11, e1004049. https://doi.org/10.1371/journal.pcbi.1004049</mixed-citation></ref><ref id="scirp.91188-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Tessier, P.M. and Lindquist, S. (2009) Unraveling Infectious Structures, Strain Variants and Species Barriers for the Yeast Prion [PSI+]. Nature Structural &amp; Molecular Biology, 16, 598-605. https://doi.org/10.1038/nsmb.1617</mixed-citation></ref><ref id="scirp.91188-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Woodsmith, J., Kamburov A. and Stelzl, U. (2013) Dual Coordination of Post Translational Modifications in Human Protein Networks. PLoS Computational Biology, 9, e1002933. https://doi.org/10.1371/journal.pcbi.1002933</mixed-citation></ref><ref id="scirp.91188-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Holman, R.C., et al. (2010) Human Prion Diseases in the United States. PLoS ONE, 5, e8521. https://doi.org/10.1371/journal.pone.0008521</mixed-citation></ref><ref id="scirp.91188-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Grizel, A.V., Rubel, A.A. and Chernoff, Y.O. (2016) Strain Conformation Controls the Specificity of Cross-Species Prion Transmission in the Yeast Model. Prion, 10, 269-282. https://doi.org/10.1080/19336896.2016.1204060</mixed-citation></ref><ref id="scirp.91188-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Cobb, N.J. and Surewicz, W.K. (2009) Prion Diseases and Their Biochemical Mechanisms. Biochemistry, 48, 2574-2585. https://doi.org/10.1021/bi900108v</mixed-citation></ref><ref id="scirp.91188-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Marin-Moreno, A., et al. (2017) Transmission and Replication of Prions. Progress in Molecular Biology and Translational Science, 150, 181-201.  
https://doi.org/10.1016/bs.pmbts.2017.06.014</mixed-citation></ref><ref id="scirp.91188-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Gambetti, P., et al. (2003) Sporadic and Familial CJD: Classification and Characterisation. British Medical Bulletin, 66, 213-239.  
https://doi.org/10.1093/bmb/66.1.213</mixed-citation></ref><ref id="scirp.91188-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Morales, R. (2017) Prion Strains in Mammals: Different Conformations Leading to Disease. PLoS Pathogens, 13, e1006323.  
https://doi.org/10.1371/journal.ppat.1006323</mixed-citation></ref><ref id="scirp.91188-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Wadsworth, J.D.F., Kong, Q., Zou, W., Parchi, P. and Chen, S.G. (2003) Molecular and Clinical Classification of Human Prion Disease. British Medical Bulletin, 66, 241-254. https://doi.org/10.1093/bmb/66.1.241</mixed-citation></ref><ref id="scirp.91188-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Chen, C. and Dong, X.P. (2016) Epidemiological Characteristics of Human Prion Diseases. Infectious Diseases of Poverty, 5, 47.  
https://doi.org/10.1186/s40249-016-0143-8</mixed-citation></ref><ref id="scirp.91188-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Reiniger, L., et al. (2013) Filamentous White Matter Prion Protein Deposition Is a Distinctive Feature of Multiple Inherited Prion Diseases. Acta Neuropathologica Communications, 1, 8. https://doi.org/10.1186/2051-5960-1-8</mixed-citation></ref><ref id="scirp.91188-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Takada, L.T. and Geschwind, M.D. (2013) Prion Diseases. Seminars in Neurology, 33, 348-356. https://doi.org/10.1055/s-0033-1359314</mixed-citation></ref><ref id="scirp.91188-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Rodriguez, M.M., et al. (2005) A Novel Mutation (G114V) in the Prion Protein Gene in a Family with Inherited Prion Disease. Neurology, 64, 1455-1477.  
https://doi.org/10.1212/01.WNL.0000158618.39527.93</mixed-citation></ref><ref id="scirp.91188-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Nakatani, E. (2016) Specific Clinical Signs and Symptoms Are Predictive of Clinical Course in Sporadic Creutzfeldt-Jakob Disease. European Journal of Neurology, 23, 1455-1462. https://doi.org/10.1111/ene.13057</mixed-citation></ref><ref id="scirp.91188-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Wijesekera, L.C. and Leigh, P.N. (2009) Amyotrophic Lateral Sclerosis. Orphanet Journal of Rare Diseases, 4, 3. https://doi.org/10.1186/1750-1172-4-3</mixed-citation></ref><ref id="scirp.91188-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Desai, M.S.J. (2000) Motor Neuron Disease: Classification and Nomenclature. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, 105-112.  
https://doi.org/10.1080/14660820050515403</mixed-citation></ref><ref id="scirp.91188-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Statland, J.M., et al. (2015) Patterns of Weakness, Classification of Motor Neuron Disease &amp; Clinical Diagnosis of Sporadic ALS. Neurologic Clinics, 33, 735-748.  
https://doi.org/10.1016/j.ncl.2015.07.006</mixed-citation></ref><ref id="scirp.91188-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Chen, S., Barohn, R.J., McVey, A.L., Katz, J.S. and Dimachkie, M.M. (2013) Genetics of Amyotrophic Lateral Sclerosis: An Update. Molecular Neurodegeneration, 8, 28. https://doi.org/10.1186/1750-1326-8-28</mixed-citation></ref><ref id="scirp.91188-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Parakh, S. and Atkin, J.D. (2016) Protein Folding Alterations in Amyotrophic Lateral Sclerosis. Brain Research, 1648, 633-649.  
https://doi.org/10.1016/j.brainres.2016.04.010</mixed-citation></ref><ref id="scirp.91188-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Renton, A.E., et al. (2011) A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 72, 257-268.  
https://doi.org/10.1016/j.neuron.2011.09.010</mixed-citation></ref><ref id="scirp.91188-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Van Blitterswijk, M., DeJesus-Hernandez, M. and Rademakers, R. (2012) How Do C9ORF72 Repeat Expansions Cause ALS and FTD: Can We Learn from Other Non-Coding Repeat Expansion Disorders? Current Opinion in Neurology, 25, 689-700. https://doi.org/10.1097/WCO.0b013e32835a3efb</mixed-citation></ref><ref id="scirp.91188-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Shaw, R. (2005) Molecular and Cellular Pathways of Neurodegeneration in Motor Neurone Disease. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1046-1057. https://doi.org/10.1136/jnnp.2004.048652</mixed-citation></ref><ref id="scirp.91188-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Foran, E. and Trotti, D. (2009) Glutamate Transporters and the Excitotoxic Path to Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis. Antioxidants &amp; Redox Signaling, 11, 1587-1602. https://doi.org/10.1089/ars.2009.2444</mixed-citation></ref><ref id="scirp.91188-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Zarei, S., et al. (2015) A Comprehensive Review of Amyotrophic Lateral Sclerosis. Surgical Neurology International, 6, 171. https://doi.org/10.4103/2152-7806.169561</mixed-citation></ref><ref id="scirp.91188-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Roos, P., Vesterberg, O. and Nordberg, M. (2006) Metals in Motor Neuron Diseases. Experimental Biology and Medicine, 231, 1481-1487.  
https://doi.org/10.1177/153537020623100906</mixed-citation></ref><ref id="scirp.91188-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Guo, C. and Kong, J. (2012) Oxidative Stress in Neurodegenerative Diseases. Neural Regeneration Research, 7, 376-385.</mixed-citation></ref><ref id="scirp.91188-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Akhtar, R. (2004) Bcl-2 Family Regulation of Neuronal Development and Neurodegeneration. Biochimica et Biophysica Acta, 1644, 189-203.  
https://doi.org/10.1016/j.bbamcr.2003.10.013</mixed-citation></ref><ref id="scirp.91188-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Hetz, C., et al. (2007) The Proapoptotic BCL-2 Family Member BIM Mediates Motoneuron Loss in a Model of Amyotrophic Lateral Sclerosis. Cell Death and Differentiation, 14, 1386-1389. https://doi.org/10.1038/sj.cdd.4402166</mixed-citation></ref><ref id="scirp.91188-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Ramesh, N. and Pandey, U.B. (2017) Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand. Frontiers in Molecular Neuroscience, 10, 263.  
https://doi.org/10.3389/fnmol.2017.00263</mixed-citation></ref><ref id="scirp.91188-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Cheon, C.K., et al. (2017) Autosomal Dominant Transmission of Complicated Hereditary Spastic Paraplegia Due to a Dominant Negative Mutation of KIF1A, SPG30 Gene. Scientific Reports, 7, Article No. 12527.  
https://doi.org/10.1038/s41598-017-12999-9</mixed-citation></ref><ref id="scirp.91188-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Ninds.nih.gov (2017) Motor Neuron Diseases Fact Sheet. National Institute of Neurological Disorders and Stroke.  
https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Motor-Neuron-Diseases-Fact-Sheet</mixed-citation></ref><ref id="scirp.91188-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Burghes, A.H.M. and Beattie, C.E. (2009) Spinal Muscular Atrophy: Why Do Low Levels of Survival Motor Neuron Protein Make Motor Neurons Sick? Nature Reviews Neuroscience, 10, 597-609. https://doi.org/10.1038/nrn2670</mixed-citation></ref><ref id="scirp.91188-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, K.R., Saigal, G., Maudsley, A.A. and Govind, V. (2011) 1H MRS of Basal Ganglia and Thalamus in Amyotrophic Lateral Sclerosis. NMR in Biomedicine, 24, 1270-1276. https://doi.org/10.1002/nbm.1687</mixed-citation></ref><ref id="scirp.91188-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Bede, P., et al. (2013) Basal Ganglia Involvement in Amyotrophic Lateral Sclerosis. Neurology, 81, 2107-2115. https://doi.org/10.1212/01.wnl.0000437313.80913.2c</mixed-citation></ref><ref id="scirp.91188-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Vargas, M.R. and Johnson, J.A. (2010) Astrogliosis in Amyotrophic Lateral Sclerosis: Role and Therapeutic Potential of Astrocytes. Neurotherapeutics, 7, 471-481.  
https://doi.org/10.1016/j.nurt.2010.05.012</mixed-citation></ref><ref id="scirp.91188-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Frakes, A.E., et al. (2014) Microglia Induce Motor Neuron Death via the Classical NF-&lt;i&gt;κ&lt;/i&gt;B Pathway in Amyotrophic Lateral Sclerosis. Neuron, 81, 1009-1023.  
https://doi.org/10.1016/j.neuron.2014.01.013</mixed-citation></ref><ref id="scirp.91188-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Polvikoski, T.M., Murray, A., Harper, P. and Neal, J. (2003) Familial Motor Neurone Disease with Dementia: Phenotypic Variation and Cerebellar Pathology. Journal of Neurology, Neurosurgery &amp; Psychiatry, 74, 1516-1520.  
https://doi.org/10.1136/jnnp.74.11.1516</mixed-citation></ref><ref id="scirp.91188-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Leighton, S.E., Burton, M.J., Lund, W.S. and Cochrane, G.M. (1994) Swallowing in Motor Neurone Disease. Journal of the Royal Society of Medicine, 87, 801-805.</mixed-citation></ref><ref id="scirp.91188-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Watts, C.R. and Vanryckeghem, M. (2001) Laryngeal Dysfunction in Amyotrophic Lateral Sclerosis: A Review and Case Report. BMC Ear, Nose and Throat Disorders, 1, 1. https://doi.org/10.1186/1472-6815-1-1</mixed-citation></ref><ref id="scirp.91188-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Atassi, N., et al. (2011) Depression in Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, 12, 109-112. https://doi.org/10.3109/17482968.2010.536839</mixed-citation></ref><ref id="scirp.91188-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Chiesa, R. and Harris, D.A. (2009) Fishing for Prion Protein Function. PLoS Biology, 7, e1000075. https://doi.org/10.1371/journal.pbio.1000075</mixed-citation></ref><ref id="scirp.91188-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Lee, Y.J. and Baskakov, I.V. (2014) The Cellular Form of the Prion Protein Guides the Differentiation of Human Embryonic Stem Cells into Neuron-, Oligodendrocyte-, and Astrocyte-Committed Lineages. Prion, 8, 266-275.  
https://doi.org/10.4161/pri.32079</mixed-citation></ref><ref id="scirp.91188-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Shi, F., et al. (2016) Cellular Prion Protein Promotes Neuronal Differentiation of Adipose-Derived Stem Cells by Upregulating miRNA-124. Journal of Molecular Neuroscience, 59, 48-55. https://doi.org/10.1007/s12031-016-0733-8</mixed-citation></ref><ref id="scirp.91188-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Mouillet-Richard, S., et al. (2000) Signal Transduction through Prion Protein. Science, 289, 1925-1928. https://doi.org/10.1126/science.289.5486.1925</mixed-citation></ref><ref id="scirp.91188-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Resenberge, U.K., Winklhofer, K.F. and Tatzelt, J. (2011) Neuroprotective and Neurotoxic Signaling by the Prion Protein. Topics in Current Chemistry, 305, 101-119. https://doi.org/10.1007/128_2011_160</mixed-citation></ref><ref id="scirp.91188-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Liebert, A., Bicknell, B. and Adams, R. (2014) Prion Protein Signaling in the Nervous System—A Review and Perspective. Signal Transduction Insights, 3, 11-32.  
https://doi.org/10.4137/STI.S12319</mixed-citation></ref><ref id="scirp.91188-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Maciejewski, A., et al. (2016) Domains of STIP1 Responsible for Regulating the PrP&lt;sup&gt;C&lt;/sup&gt;-Dependent Amyloid-&lt;i&gt;β&lt;/i&gt; Oligomer Toxicity. Biochemical Journal, 473, 2119-2130. https://doi.org/10.1042/BCJ20160087</mixed-citation></ref><ref id="scirp.91188-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Xu, F., Karnaukhova, E. and  Vostal, J.G. (2008) Human Cellular Prion Protein Interacts Directly with Clusterin Protein. Biochimica et Biophysica Acta, 1782, 615-620. https://doi.org/10.1016/j.bbadis.2008.08.004</mixed-citation></ref><ref id="scirp.91188-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Cai, Y., et al. (2016) Interplay of Endoplasmic Reticulum Stress and Autophagy in Neurodegenerative Disorders. Autophagy, 12, 225-244.  
https://doi.org/10.1080/15548627.2015.1121360</mixed-citation></ref><ref id="scirp.91188-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Gibbings, D., et al. (2012) Human Prion Protein Binds Argonaute and Promotes Accumulation of microRNA Effector Complexes. Nature Structural &amp; Molecular Biology, 19, 517-524. https://doi.org/10.1038/nsmb.2273</mixed-citation></ref><ref id="scirp.91188-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">David, R. (2011) BAG6 &amp; Mislocalized Proteins. Nature Reviews Molecular Cell Biology, 12, 550. https://doi.org/10.1038/nrm3167</mixed-citation></ref><ref id="scirp.91188-ref72"><label>72</label><mixed-citation publication-type="other" xlink:type="simple">Das, J. and Yu, H. (2012) HINT: High-Quality Protein Interactomes and Their Applications in Understanding Human Disease. BMC Systems Biology, 6, 92.  
https://doi.org/10.1186/1752-0509-6-92</mixed-citation></ref><ref id="scirp.91188-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">Szklarczyk, D., et al. (2015) STRING v10: Protein–Protein Interaction Networks, Integrated over the Tree of Life. Nucleic Acids Research, 43, D447-D452.  
https://doi.org/10.1093/nar/gku1003</mixed-citation></ref><ref id="scirp.91188-ref74"><label>74</label><mixed-citation publication-type="other" xlink:type="simple">Stark, C., et al. (2006) BioGRID: A General Repository for Interaction Datasets. Nucleic Acids Research, 34, D535-D539. https://doi.org/10.1093/nar/gkj109</mixed-citation></ref><ref id="scirp.91188-ref75"><label>75</label><mixed-citation publication-type="other" xlink:type="simple">Keshava Prasad, T.S., et al. (2009) Human Protein Reference Database—2009 Update. Nucleic Acids Research, 37, D767-D772.  
https://doi.org/10.1093/nar/gkn892</mixed-citation></ref><ref id="scirp.91188-ref76"><label>76</label><mixed-citation publication-type="other" xlink:type="simple">Chatr-aryamontri, A., et al. (2007) MINT: The Molecular INTeraction Database. Nucleic Acids Research, 35, D572-D574. https://doi.org/10.1093/nar/gkl950</mixed-citation></ref><ref id="scirp.91188-ref77"><label>77</label><mixed-citation publication-type="other" xlink:type="simple">Peri, S., et al. (2003) Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans. Genome Research, 13, 2363-2371. https://doi.org/10.1101/gr.1680803</mixed-citation></ref><ref id="scirp.91188-ref78"><label>78</label><mixed-citation publication-type="other" xlink:type="simple">Warde-Farley, D., et al. (2010) The GeneMANIA Prediction Server: Biological Network Integration for Gene Prioritization and Predicting Gene Function. Nucleic Acids Research, 38, W214-W220. https://doi.org/10.1093/nar/gkq537</mixed-citation></ref><ref id="scirp.91188-ref79"><label>79</label><mixed-citation publication-type="other" xlink:type="simple">Rolland, T., et al. (2014) A Proteome-Scale Map of the Human Interactome Network. Cell, 159, 1212-1226. https://doi.org/10.1016/j.cell.2014.10.050</mixed-citation></ref><ref id="scirp.91188-ref80"><label>80</label><mixed-citation publication-type="other" xlink:type="simple">Kurschner, C. and Morgan, J.I. (1995) The Cellular Prion Protein (PrP) Selectively Binds to Bcl-2 in the Yeast Two-Hybrid System. Molecular Brain Research, 30, 165-168. https://doi.org/10.1016/0169-328X(95)00013-I</mixed-citation></ref><ref id="scirp.91188-ref81"><label>81</label><mixed-citation publication-type="other" xlink:type="simple">Ferreiro, E., et al. (2007) Bcl-2 Overexpression Protects Against Amyloid-Beta and Prion Toxicity in GT1-7 Neural Cells. Journal of Alzheimer’s Disease, 12, 223-228.  
https://doi.org/10.3233/JAD-2007-12303</mixed-citation></ref><ref id="scirp.91188-ref82"><label>82</label><mixed-citation publication-type="other" xlink:type="simple">Kralovicova, S., et al. (2009) The Effects of Prion Protein Expression on Metal Metabolism. Molecular and Cellular Neuroscience, 41, 135-147.  
https://doi.org/10.1016/j.mcn.2009.02.002</mixed-citation></ref><ref id="scirp.91188-ref83"><label>83</label><mixed-citation publication-type="other" xlink:type="simple">Kaiser, D.M., et al. (2012) Amyloid Beta Precursor Protein and Prion Protein Have a Conserved Interaction Affecting Cell Adhesion and CNS Development. PLoS ONE, 7, e51305. https://doi.org/10.1371/journal.pone.0051305</mixed-citation></ref><ref id="scirp.91188-ref84"><label>84</label><mixed-citation publication-type="other" xlink:type="simple">McHugh, P.C., et al. (2012) Prion Protein Expression Alters APP Cleavage without Interaction with BACE-1. Neurochemistry International, 61, 672-680.  
https://doi.org/10.1016/j.neuint.2012.07.002</mixed-citation></ref><ref id="scirp.91188-ref85"><label>85</label><mixed-citation publication-type="other" xlink:type="simple">Bai, Y., et al. (2008) The in Vivo Brain Interactome of the Amyloid Precursor Protein. Molecular &amp; Cellular Proteomics, 7, 15-34.  
https://doi.org/10.1074/mcp.M700077-MCP200</mixed-citation></ref><ref id="scirp.91188-ref86"><label>86</label><mixed-citation publication-type="other" xlink:type="simple">Satoh, J., et al. (2008) Protein Microarray Analysis Identifies Human Cellular Prion Protein Interactors. Neuropathology and Applied Neurobiology, 35, 16-35.  
https://doi.org/10.1111/j.1365-2990.2008.00947.x</mixed-citation></ref><ref id="scirp.91188-ref87"><label>87</label><mixed-citation publication-type="other" xlink:type="simple">Klamt, F., et al. (2001) Imbalance of Antioxidant Defense in Mice Lacking Cellular Prion Protein. Free Radical Biology &amp; Medicine, 30, 1137-1144.  
https://doi.org/10.1016/S0891-5849(01)00512-3</mixed-citation></ref><ref id="scirp.91188-ref88"><label>88</label><mixed-citation publication-type="other" xlink:type="simple">Spee, B., et al. (2006) Copper Metabolism and Oxidative Stress in Chronic Inflammatory and Cholestatic Liver Diseases in Dogs. Journal of Veterinary Internal Medicine, 20, 1085-1092. https://doi.org/10.1111/j.1939-1676.2006.tb00706.x</mixed-citation></ref><ref id="scirp.91188-ref89"><label>89</label><mixed-citation publication-type="other" xlink:type="simple">Stetler, R.A., et al. (2010) Heat Shock Proteins: Cellular and Molecular Mechanisms in the CNS. Progress in Neurobiology, 92, 184-211.  
https://doi.org/10.1016/j.pneurobio.2010.05.002</mixed-citation></ref><ref id="scirp.91188-ref90"><label>90</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, P.N. and Strasser, A. (2011) The Role of Bcl-2 and Its Pro-Survival Relatives in Tumourigenesis and Cancer Therapy. Cell Death and Differentiation, 18, 1414-1424. https://doi.org/10.1038/cdd.2011.17</mixed-citation></ref><ref id="scirp.91188-ref91"><label>91</label><mixed-citation publication-type="other" xlink:type="simple">Brown, D.R. and Besinger, A. (1998) Prion Protein Expression and Superoxide Dismutase Activity. Biochemical Journal, 334, 423-429.  
https://doi.org/10.1042/bj3340423</mixed-citation></ref><ref id="scirp.91188-ref92"><label>92</label><mixed-citation publication-type="other" xlink:type="simple">Hutter, G., Heppner, F.L. and Aguzzi, A. (2003) No Superoxide Dismutase Activity of Cellular Prion Protein in Vivo. Biological Chemistry, 384, 1279-1285.  
https://doi.org/10.1515/BC.2003.142</mixed-citation></ref><ref id="scirp.91188-ref93"><label>93</label><mixed-citation publication-type="other" xlink:type="simple">Jones, S., et al. (2005) Recombinant Prion Protein Does Not Possess SOD-1 Activity. Biochemical Journal, 392, 309-312. https://doi.org/10.1042/BJ20051236</mixed-citation></ref><ref id="scirp.91188-ref94"><label>94</label><mixed-citation publication-type="other" xlink:type="simple">Choi, C.J., et al. (2006) Interaction of Metals with Prion Protein: Possible Role of Divalent Cations in the Pathogenesis of Prion Diseases. Neurotoxicology, 27, 777-787. https://doi.org/10.1016/j.neuro.2006.06.004</mixed-citation></ref><ref id="scirp.91188-ref95"><label>95</label><mixed-citation publication-type="other" xlink:type="simple">Toni, M., Massimino, M.L., Griffoni, C., Salvato, B., Tomasi, V. and Spisni, E. (2005) Extracellular Copper Ions Regulate Cellular Prion Protein (PrPC) Expression and Metabolism in Neuronal Cells. FEBS Letters, 579, 741-744.  
https://doi.org/10.1016/j.febslet.2004.12.053</mixed-citation></ref><ref id="scirp.91188-ref96"><label>96</label><mixed-citation publication-type="other" xlink:type="simple">Peggion, C., Bertoli, A. and Sorgato, M.C. (2017) Almost a Century of Prion Protein(s): From Pathology to Physiology, and Back to Pathology. Biochemical and Biophysical Research Communications, 483, 1148-1155.  
https://doi.org/10.1016/j.bbrc.2016.07.118</mixed-citation></ref><ref id="scirp.91188-ref97"><label>97</label><mixed-citation publication-type="other" xlink:type="simple">Herms, J.W., Tings, T., Dunker, S. and Kretzschmar, H.A. (2001) Prion Protein Affects Ca&lt;sup&gt;2+&lt;/sup&gt;-Activated K&lt;sup&gt;+&lt;/sup&gt; Currents in Cerebellar Purkinje Cells. Neurobiology of Disease, 8, 324-330. https://doi.org/10.1006/nbdi.2000.0369</mixed-citation></ref><ref id="scirp.91188-ref98"><label>98</label><mixed-citation publication-type="other" xlink:type="simple">Korte, S., et al. (2003) Modulation of L-Type Voltage-Gated Calcium Channels by Recombinant Prion Protein. Journal of Neurochemistry, 87, 1037-1042.  
https://doi.org/10.1046/j.1471-4159.2003.02080.x</mixed-citation></ref><ref id="scirp.91188-ref99"><label>99</label><mixed-citation publication-type="other" xlink:type="simple">Choi, D.K., Su Kim, I. and Do, J.H. (2014) Signaling Pathway Analysis of MPP&lt;sup&gt;+&lt;/sup&gt;-Treated Human Neuroblastoma SH-SY5Y Cells. Biotechnology and Bioprocess Engineering, 19, 332-340. https://doi.org/10.1007/s12257-013-0754-x</mixed-citation></ref><ref id="scirp.91188-ref100"><label>100</label><mixed-citation publication-type="other" xlink:type="simple">Macario, A.J. and Conway de Macario, E. (2005) Sick Chaperones, Cellular Stress, and Disease. New England Journal of Medicine, 353, 1489-1501.  
https://doi.org/10.1056/NEJMra050111</mixed-citation></ref><ref id="scirp.91188-ref101"><label>101</label><mixed-citation publication-type="other" xlink:type="simple">Goold, R., McKinnon, C. and Tabrizi, S.J. (2015) Prion Degradation Pathways: Potential for Therapeutic Intervention. Molecular and Cellular Neurosciences, 66, 12-20. https://doi.org/10.1016/j.mcn.2014.12.009</mixed-citation></ref><ref id="scirp.91188-ref102"><label>102</label><mixed-citation publication-type="other" xlink:type="simple">Hishiya, A. and Takayama, S. (2008) Molecular Chaperones as Regulators of Cell Death. Oncogene, 27, 6489-6506. https://doi.org/10.1038/onc.2008.314</mixed-citation></ref><ref id="scirp.91188-ref103"><label>103</label><mixed-citation publication-type="other" xlink:type="simple">Proescher, J.B., Son, M., Elliott, J.L. and Culotta, V.C. (2008) Biological Effects of CCS in the Absence of SOD1 Enzyme Activation: Implications for Disease in a Mouse Model for ALS. Human Molecular Genetics, 17, 1728-1737.  
https://doi.org/10.1093/hmg/ddn063</mixed-citation></ref><ref id="scirp.91188-ref104"><label>104</label><mixed-citation publication-type="other" xlink:type="simple">Aguzzi, A. and Calella, A.M. (2009) Prions: Protein Aggregation and Infectious Diseases. Physiological Reviews, 89, 1105-1152.  
https://doi.org/10.1152/physrev.00006.2009</mixed-citation></ref><ref id="scirp.91188-ref105"><label>105</label><mixed-citation publication-type="other" xlink:type="simple">Brown, D.R. (2004) Role of the Prion Protein in Copper Turnover in Astrocytes. Neurobiology of Disease, 15, 534-543. https://doi.org/10.1016/j.nbd.2003.11.009</mixed-citation></ref><ref id="scirp.91188-ref106"><label>106</label><mixed-citation publication-type="other" xlink:type="simple">Desai, V. and Kaler, S.G. (2008) Role of Copper in Human Neurological Disorders. American Journal of Clinical Nutrition, 88, 855s-858s.  
https://doi.org/10.1093/ajcn/88.3.855S</mixed-citation></ref><ref id="scirp.91188-ref107"><label>107</label><mixed-citation publication-type="other" xlink:type="simple">Deriziotis, B. and Tabrizi, S.J. (2008) Prions and the Proteasome. Biochimica et Biophysica Acta, 1782, 713-722. https://doi.org/10.1016/j.bbadis.2008.06.011</mixed-citation></ref><ref id="scirp.91188-ref108"><label>108</label><mixed-citation publication-type="other" xlink:type="simple">Yano, M., Koumoto, Y., Kanesaki, Y., Wu, X. and Kido, H. (2004) 20S Proteasome Prevents Aggregation of Heat-Denatured Proteins without PA700 Regulatory Subcomplex like a Molecular Chaperone. Biomacromolecules, 5, 1465-1469.  
https://doi.org/10.1021/bm049957a</mixed-citation></ref><ref id="scirp.91188-ref109"><label>109</label><mixed-citation publication-type="other" xlink:type="simple">Rowland, L.P. and Shneider, N.A. (2001) Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 344, 1688-1700.  
https://doi.org/10.1056/NEJM200105313442207</mixed-citation></ref><ref id="scirp.91188-ref110"><label>110</label><mixed-citation publication-type="other" xlink:type="simple">Steele, A.D., Lindquist, S. and Aguzzi, A. (2007) The Prion Protein Knockout Mouse: A Phenotype under Challenge. Prion, 1, 83-93.  
https://doi.org/10.4161/pri.1.2.4346</mixed-citation></ref><ref id="scirp.91188-ref111"><label>111</label><mixed-citation publication-type="other" xlink:type="simple">Winklhofer, K.F., Tatzelt, J. and Haass, C. (2008) The Two Faces of Protein Misfolding: Gain- and Loss-of-Function in Neurodegenerative Diseases. The EMBO Journal, 27, 336-349. https://doi.org/10.1038/sj.emboj.7601930</mixed-citation></ref><ref id="scirp.91188-ref112"><label>112</label><mixed-citation publication-type="other" xlink:type="simple">Saccon, R.A., Bunton-Stasyshyn, R.K.A., Fisher, E.M.C. and Fratta, P. (2013) Is SOD1 Loss of Function Involved in Amyotrophic Lateral Sclerosis? Brain, 136, 2342-2358. https://doi.org/10.1093/brain/awt097</mixed-citation></ref><ref id="scirp.91188-ref113"><label>113</label><mixed-citation publication-type="other" xlink:type="simple">Li, J., Wuliji, O., Li, W., Jiang, Z.G. and Ghanbari, H.A. (2013) Oxidative Stress and Neurodegenerative Disorders. International Journal of Molecular Sciences, 14, 24438-24475. https://doi.org/10.3390/ijms141224438</mixed-citation></ref><ref id="scirp.91188-ref114"><label>114</label><mixed-citation publication-type="other" xlink:type="simple">Onodera, T., Sakudo, A., Tsubone, H. and Itohara, S. (2014) Review of Studies That Have Used Knockout Mice to Assess Normal Function of Prion Protein under Immunological or Pathophysiological Stress. Microbiology and Immunology, 58, 361-374. https://doi.org/10.1111/1348-0421.12162</mixed-citation></ref><ref id="scirp.91188-ref115"><label>115</label><mixed-citation publication-type="other" xlink:type="simple">Freixes, M., et al. (2004) Clusterin Solubility and Aggregation in Creutzfeldt-Jakob Disease. Acta Neuropathologica, 108, 295-301.  
https://doi.org/10.1007/s00401-004-0891-6</mixed-citation></ref><ref id="scirp.91188-ref116"><label>116</label><mixed-citation publication-type="other" xlink:type="simple">Ciechanover, A. and Kwon, Y.T. (2015) Degradation of Misfolded Proteins in Neurodegenerative Diseases: Therapeutic Targets and Strategies. Experimental and Molecular Medicine, 47, e147. https://doi.org/10.1038/emm.2014.117</mixed-citation></ref><ref id="scirp.91188-ref117"><label>117</label><mixed-citation publication-type="other" xlink:type="simple">Hall, T.M. (2005) Structure and Function of Argonaute Proteins. Structure, 13, 1403-1408. https://doi.org/10.1016/j.str.2005.08.005</mixed-citation></ref><ref id="scirp.91188-ref118"><label>118</label><mixed-citation publication-type="other" xlink:type="simple">Wilczynska, A. and Bushell, M. (2015) The Complexity of miRNA-Mediated Repression. Cell Death and Differentiation, 22, 22-33.  
https://doi.org/10.1038/cdd.2014.112</mixed-citation></ref><ref id="scirp.91188-ref119"><label>119</label><mixed-citation publication-type="other" xlink:type="simple">Gibbings, D., et al. (2012) Human Prion Protein Binds Argonaute and Promotes Accumulation of microRNA Effector Complexes. Nature Structural &amp; Molecular Biology, 19, 517-524. https://doi.org/10.1038/nsmb.2273</mixed-citation></ref></ref-list></back></article>